The deal size was increased to $125M in common stock from $100M in common stock. Goldman Sachs, BofA, Barclays and Oppenheimer acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals announces $100M common stock offering
- Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies
- Tarsus Pharmaceuticals’ Earnings Call Highlights Success and Challenges
- Hold Rating for Tarsus Pharmaceuticals Amid Strong Sales and Market Uncertainties
- Guggenheim ups Tarsus Pharmaceuticals price target, would buy on weakness